Here's why ARK Invest's lead stock picker thinks these beaten-down growth shares can bounce back. Read More...
Reuters
GSK tops quarterly forecasts, helped by COVID-19 treatment and Shingrix
British pharmaceuticals giant GSK beat analyst expectations for its first-quarter results on Wednesday and stood by its 2022 forecasts, after buoyant sales of its COVID-19 treatment which has now been withdrawn from the U.S. market. The earnings beat, with lifted GSK’s shares more than 1% in early trade, comes ahead of the July listing of its consumer healthcare venture with Pfizer, christened Haleon, which has put GSK’s future in focus. Chief Executive Emma Walmsley faces pressure from activist investor Elliot to shore up its pipeline.
Add Comment